BIOAMBER INC. (NYSE:BIOA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Executive Officer

On September 11, 2017, the Board of Directors of BioAmber, Inc. (the “Company”) appointed of Richard Eno as Chief Executive Officer of the Company.Mr. Eno will also become a member of the Company’s Board of Directors. Both appointments are effective September 18, 2017.

Mr. Eno has over 30 years of related management experience in the energy, chemicals, biotechnology and materials industries, including over five years as President, CEO and Board member of a publicly traded industrial biotechnology company.Mr. Eno began his career in Chevron's chemical operations with roles of increasing responsibility in engineering, manufacturing and construction operations.He then entered management consulting where he specialized in addressing critical strategic and operational issues facing company leadership in the chemical and energy industries.In 2008, he took up leadership of Metabolix, an industrial biotechnology company commercializing a range of unique bio-based, biodegradable polymers.Most recently, Mr. Eno has been a senior partner at a global management consultancy, Roland Berger, focused on the chemicals industry. He has a Bachelor of Science in Chemical Engineering from Cornell University, a Master in Business Administration from the University of Houston and is a Chartered Financial Analyst (CFA).

In connection with Mr. Eno’s appointment as Chief Executive Officer of the Company, the Company entered into an employment agreement with Mr. Eno (the “Employment Agreement”). to the Employment Agreement, Mr. Eno will be paid (i) a base salary of $500,000, which is subject to review and adjustment in accordance with Company policy, and (ii) an annual target cash bonus payable in the first quarter of each fiscal year equal to 70% of his gross base salary, based on performance and subject to the evaluation and determination of the Company and the Board. In connection with his employment with the Company, the Board granted Mr. Eno an option to purchase 500,000 shares of common stock at a price per share equal to the fair market value of the Company’s common stock on the date of grant in accordance with the terms of the Company’s Equity Grant Award Policy. The Company also agreed to grant Mr. Eno another 500,000 shares of common stock as of March 1, 2018 at a price per share equal to the fair market value of the Company’s common stock on the date of grant in accordance with the terms of the Company’s Equity Grant Award Policy. The options granted will vest on a monthly basis over a period of 36 months following each grant date as per the Company’s Equity Grant Award Policy. The Company shall also grant to Mr. Eno, in the first quarter of each fiscal year, stock options to purchase shares of the Company, restricted stock units or other similar awards based on his and the Company’s performance, such grants to be at the discretion of the Board and in accordance with Company policies.

The Employment Agreement shall be in effect for an indeterminate period and Mr. Eno shall have the right to terminate the Employment Agreement at any time by giving a three month written notice to the Company.In the event that the Company terminates Mr. Eno’s employment for reasons other than his death or for cause, Mr. Eno shall receive a severance payment equal to (i) 18 month’s gross base salary, (ii) the targeted bonus for such period, (iii) immediate vesting of his stock options having a vesting date within 12 months following the date of termination and (iv) continuation of his fringe benefits for a period of 12 months following the date of termination. The foregoing notwithstanding, in the event that the Company terminates the employment of Mr. Eno for reasons other than his death or for cause in the six months following a transaction involving a change of control of the Company, Mr. Eno will be entitled to the following severance payment: (i) 24 month’s gross base salary, (ii) the targeted bonus for such period, (iii) immediate vesting of all his stock options (iv) continuation of his fringe benefits for a period of 18 months following the date of termination .The Employment Agreement also contains a non-solicit and non-compete clause during his employment and for a period of twelve months thereafter.

A copy of the related press release is furnished with this report as Exhibit99.1.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

BioAmber Inc. Exhibit
EX-99.1 2 bioa-ex991_6.htm EX-99.1 bioa-ex991_6.htm Exhibit 99.1     BioAmber Announces New Chief Executive Officer   Montreal,…
To view the full exhibit click here

About BIOAMBER INC. (NYSE:BIOA)

BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.